Arizona is putting $5 million in state money behind a clinical trial of ibogaine, a psychoactive compound that remains federally illegal and carries a documented risk of fatal heart rhythm disturbance.
Barrow Neurological Institute received the grant from the Arizona Department of Health Services to conduct a Phase 1/2 trial in people with neurological conditions including traumatic brain injury, the institute announced. The study is double-blind and placebo-controlled, aims to enroll 40 participants with chronic TBI symptoms, and will split them evenly between ibogaine and placebo. Researchers hope to enroll the first participant in 2027.
Two facts belong together in any account of this trial. Ibogaine is a Schedule I controlled substance in the United States, meaning it has no federally accepted medical use. And ibogaine has been associated with deaths from cardiac arrhythmia in unregulated settings abroad.
What a Phase 1/2 Trial Is Designed to Answer
The trial's stage sets a firm ceiling on what it can conclude, and that limit should be stated before any discussion of promise.
Early-phase trials exist primarily to establish safety, tolerability and appropriate dosing, and to look for a preliminary signal that a compound does anything at all. They are not designed or sized to prove that a treatment works.
Recent open-label studies have reported improvements in PTSD symptoms, cognitive function and quality of life among veterans, which is what generated the political and public interest behind the appropriation.
Forty participants is a small trial. With 20 people receiving the drug, the study can detect only large effects, and it cannot reliably detect uncommon adverse events. A safety signal occurring in one patient in 200 would very likely not appear at all.
The randomized, double-blind, placebo-controlled design is a genuine strength and is what distinguishes this trial from the open-label reports that have driven public interest. In open-label studies, participants know what they received, which is a serious problem for outcomes measured by self-reported symptoms in a population that has often traveled far and paid considerable sums seeking help.
Researchers plan standardized assessments of TBI symptoms and quality of life, alongside tests measuring physical changes that might accompany reported improvement. Objective measures matter here, because subjective improvement alone is difficult to interpret in a condition with fluctuating symptoms. The work involves the Barrow Neuro Analytics Center and researchers from Arizona State University. Dr. Michael Lawton, Barrow's president and chief executive, framed the trial as part of a broader effort to understand how the brain functions as the mind.
The Cardiac Risk Is the Central Safety Question
This is the part that most coverage of ibogaine handles poorly, and it is not a hypothetical concern.
Ibogaine prolongs the QT interval, a measure of the heart's electrical recovery between beats. QT prolongation can trigger torsades de pointes, a ventricular arrhythmia that can cause sudden cardiac arrest. Deaths have been documented at unregulated ibogaine clinics operating outside the United States, where medical screening, cardiac monitoring and emergency capability vary enormously.
The drug also has a long duration of action, producing an intense altered state lasting many hours, which places additional demands on monitoring.
Risk rises with pre-existing cardiac conditions, electrolyte abnormalities including low potassium and magnesium, and concurrent use of other QT-prolonging medications, a category that includes many antidepressants, antipsychotics and antibiotics. That combination is common in patients with TBI and PTSD.
This is precisely why the trial setting matters. A study at a neurological institute involves cardiac screening, continuous monitoring and resuscitation capability. None of that is guaranteed when someone travels abroad to a clinic found online.
Nobody with a brain injury should seek ibogaine outside a regulated trial. That is not a cautious framing; it is the specific circumstance in which people have died.
Why State Legislatures Are Funding This
The political pathway explains why the money exists, and it is worth understanding without endorsing or dismissing it.
The appropriation originated as House Bill 2871 and was enacted through Arizona's fiscal year 2026 budget, signed in late June. Former US Senator Kyrsten Sinema advocated for the measure as a private citizen and worked to raise a private match. Legislators heard testimony from veterans describing persistent cognitive and mental health effects they said existing treatments had not resolved.
The Arizona Department of Health Services opened a competitive application process through the Arizona Biomedical Research Center, which could have funded one to three trials or declined to award anything.
Texas has pursued similar funding, and Arizona became the second state to appropriate public money for ibogaine research. The driver in both states is the same: roughly half of people with traumatic brain injury experience incomplete recovery or lingering symptoms beyond six months, and treatment options for that group are limited.
Legislative funding of one specific investigational compound is unusual in American biomedical research. It bypasses the peer-reviewed grant process that normally determines which therapies get tested, which is a reasonable subject of debate independent of whether ibogaine turns out to help anyone.
What Patients and Families Should Do Now
The practical answer is to wait and to be careful in the meantime.
No participant will be enrolled before 2027, and results would follow years later. Nothing about this grant makes ibogaine available, and anyone offering it in the United States is operating illegally. Barrow lists its open studies through its clinical trials directory rather than through third parties.
People living with persistent post-concussive symptoms have evidence-based options worth pursuing now, including vestibular and vision therapy, graded exercise programs, cognitive rehabilitation, sleep evaluation and treatment for co-occurring depression, anxiety and PTSD. Specialized TBI and polytrauma programs exist within the VA system for veterans.
Anyone considering any psychedelic-adjacent treatment should disclose all medications to a clinician, particularly antidepressants, and should understand that supplement and clinic marketing in this space frequently outruns the evidence.
MedicalDaily will report the trial's registration details, enrollment criteria, and eventual results.
Frequently Asked Questions
What did Arizona fund? A $5 million grant to Barrow Neurological Institute for a Phase 1/2 trial of ibogaine in people with neurological conditions including traumatic brain injury.
How large is the trial? It aims to enroll 40 participants, half receiving ibogaine and half placebo, with first enrollment targeted for 2027.
Is ibogaine legal? No. It is a Schedule I controlled substance in the United States, with no federally accepted medical use.
What is the main safety concern? Ibogaine prolongs the QT interval and can trigger a dangerous heart arrhythmia. Deaths have occurred at unregulated clinics abroad.
Will this trial show whether it works? No. Early-phase trials assess safety, dosing and preliminary signal. They are not sized to prove benefit.
Can I get ibogaine now? Not legally in the United States, and seeking it abroad carries documented cardiac risk without medical monitoring.
What can help persistent TBI symptoms today? Vestibular and vision therapy, graded exercise, cognitive rehabilitation, sleep evaluation and treatment of co-occurring mental health conditions.
